Sionna Therapeutics, Inc. (SION) Stock Analysis

Q: What is the SION stock price target?

Take-profit $43.79 (+9.7% upside). Prior stop was $37.11.

Q: What are the risks of investing in SION?

Concentration risk — Product: SION-719 and SION-451; Quality below floor (1.4 < 4.0); Quality below floor (1.4 < 4.0); Momentum score 4.3/10 — below 4.5 minimum.

Q: Is SION overvalued or undervalued?

Sionna Therapeutics, Inc. trades at a P/E of N/A (forward -15.0). TrendMatrix value score: 6.0/10. Overall verdict: Sell.

Q: What do analysts say about SION?

16 analysts cover SION with a consensus score of 4.2/5. Average price target: $50.

Range Bound setup

SellModerate ConfidenceUpdated 2026-05-02

Healthcare · Biotechnology

Earnings in 4 days (2026-05-05). Expect elevated volatility around the report — consider waiting for post-earnings price action before new entries.

Sell if holding. Engine safety override at $39.90: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 14%; Elevated put/call ratio: 5.40; Below-average business quality.

Sionna Therapeutics is a clinical-stage biopharmaceutical company developing NBD1 stabilizer-based therapies for cystic fibrosis. Lead candidates SION-719 (Phase 2a) and SION-451 (Phase 1) target the F508del mutation affecting ~90% of CF patients. As of Dec 31, 2025, the company... Read more

$39.90+9.7% A.UpsideScore 4.5/10#135 of 158 Biotechnology

Stop $37.11Target $43.79(analyst − 13%)A.R:R 0.7:1

Analyst target$50.33+26.1%9 analysts

$43.79our TP

$39.90price

$50.33mean

$24

$63

Passes 4/7 gates (clean insider activity, no SEC red flags, news boost analyst 0.70, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 4d<=7d. Suitability: aggressive.

Thesis

Rewards

Recent Analyst detected in news

Risks

Concentration risk — Product: SION-719 and SION-451

Quality below floor (1.4 < 4.0)

Key Metrics

P/E (TTM)—

P/E (Fwd)-15.0

Mkt Cap$1.7B

EV/EBITDA-17.1

Profit Mgn0.0%

ROE-31.8%

Rev Growth—

Beta—

DividendNone

Rating analysts16

Quality Signals

Piotroski F2/9

Options Flow

P/C5.40bearish

IV104%elevated

Max Pain$25-37.3% vs spot

Concentration Risks(10-K Item 1A)

HIGHProductSION-719 and SION-451
10-K Item 1A: 'We are substantially dependent on the success of at least one of our NBD1 stabilizer product candidates, SION-719 and SION-451'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer

Rating Breakdown

2 floor-breakers

Overall = weighted sum of the 10 dimension scores. Fundamentals (Value/Quality/Growth) carry 45%; market signals (Momentum/Sentiment/Insider/Peer) carry 40%; structure (Technical/Risk/Catalyst) carries 15%.

DimensionScoreWeightContribution

Value6.015%0.90

Quality1.415%0.21

Growth5.015%0.75

Momentum4.310%0.43

Sentiment8.210%0.82

Insider Activity3.010%0.30

Peer Rank4.510%0.45

Technical Setup6.15%0.30

Risk Profile1.25%0.06

Catalyst4.75%0.24

Overall (Σ contributions)4.46

Small float-rounding may cause last-digit differences between this sum and the displayed Overall.

Volatile — 7.9% daily ATR makes tight stops impractical. Position-size conservatively.static

Volatility

0.0

Put Call

0.0

Implied Vol

0.0

Days To Cover

0.2

Debt Equity

2.2

Short Interest

3.0

Max Pain Risk

3.0

Elevated put/call: 5.40High IV: 104%Above max pain $25Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)

Quality below the gate floor. Component breakdown shows what dragged the score down.static

Roe

0.0

Roa

0.0

Gross Margin

0.0

Operating Margin

0.0

Net Margin

0.0

Fcf Quality

0.0

Piotroski F

2.2

Current Ratio

5.0

Moat

5.0

Cash-burning (FCF negative)No competitive moatWeak Piotroski F-Score: 2/9Quality concerns

GatesMomentum 4.3<4.5A.R:R 0.7 < 1.5@spotEARNINGS PROXIMITY 4d<=7dInsider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.70SEMI CYCLE PEAK CLEARRange BoundSuitability: Aggressive

RSI

45 · Neutral

↓ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $35.10Resistance $46.46

Price Targets

$37

$44

A.Upside+9.7%

A.R:R0.7:1

Position Sizing

ConvictionNone

Suggested %0.5%

Max %1%

RegimeSteady

Risk Alerts

! Quality below floor (1.4 < 4.0)

! Momentum score 4.3/10 — below 4.5 minimum

! Reward/Risk 0.7:1 at current price — below 1.5:1 minimum

Earnings

2/4 beats

Next Earnings2026-05-05 (4d)

Verdict History

reverse chrono — latest first

Loading history...

Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.

Frequently Asked Questions

Is SION stock a buy right now?

Sell if holding. Engine safety override at $39.90: Quality below floor (1.4 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.5/10. Specifically: High short interest: 14%; Elevated put/call ratio: 5.40; Below-average business quality. Chart setup: RSI 45 mid-range, Bollinger mid-band. Prior stop was $37.11. Score 4.5/10, moderate confidence.

What is the SION stock price target?

Take-profit target: $43.79 (+9.7% upside). Prior stop was $37.11. Stop-loss: $37.11.

What are the risks of investing in SION?

Concentration risk — Product: SION-719 and SION-451; Quality below floor (1.4 < 4.0).

Is SION overvalued or undervalued?

Sionna Therapeutics, Inc. trades at a P/E of N/A (forward -15.0). TrendMatrix value score: 6.0/10. Verdict: Sell.

What do analysts say about SION?

16 analysts cover SION with a consensus score of 4.2/5. Average price target: $50.

What does Sionna Therapeutics, Inc. do?Sionna Therapeutics is a clinical-stage biopharmaceutical company developing NBD1 stabilizer-based therapies for cystic...